Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. Company
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
Real-time Estimate Cboe Europe  -  09:04 2022-12-05 am EST
49.50 CHF   +0.30%
11/24Basilea Pharmaceutica : Updated November 24, 2022
PU
11/02Basilea To Sell Preclinical CLK Kinase Inhibitors To Twentyeight-Seven Therapeutics
MT
11/02Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba for the treatment of invasive fungal infections, and Zevtera for the treatment of severe bacterial infections. Additionally, organization is conducting clinical studies with targeted drug candidates for the treatment of a range of cancers. The Company has several preclinical assets in both cancer and infectious diseases in its portfolio. Company's products are present in United States, Canda, Europe, Asia, and Africa.

Number of employees : 154 people.
Sales per Business
20202021Delta
Innovative Pharmaceutical Products127.63100%148.12100% +16.06%
CHF in Million
Sales per region
20202021Delta
Ireland56.9044.6%62.1041.9% +9.14%
Japan40.1031.4%56.5038.1% +40.9%
United States13.2010.3%14.509.8% +9.85%
Switzerland--3.702.5%-
Uruguay4.803.8%3.402.3% -29.17%
Sweden2.902.3%2.801.9% -3.45%
Jordan--2.201.5%-
Canada--2.201.5%-
Other4.403.4%0.700.5% -84.09%
CHF in Million
Managers
Name Title Age Since
David Veitch Chief Executive Officer 56 2018
Adesh Kaul Head-Corporate Development 47 -
Laurenz Kellenberger, Dr. Chief Scientific Officer 54 2009
Marc Engelhardt, Dr. Head-Clinical Research 57 2010
Gerrit Hauck, Dr. Chief Technology Officer 57 2018
Peer Nils Schr÷der, Dr. Head-Corporate Communications & Investor Relations - -
Damian Heller Deputy General Counsel & Global Compliance Officer 55 2015
Ursula Eberhardt Head-Global Human Resources 59 2017
Members of the board
Name Title Age Since
Domenico Scala, Dr. Chairman 57 2016
Steven D. Skolsky Independent Non-Executive Director 65 2010
Thomas Werner, Dr. Vice Chairman 65 2018
Alf Gunnar Martin Nicklasson, Dr. Independent Non-Executive Director 66 2016
Nicole M. Onetto, Dr. Independent Non-Executive Director 68 2017
Leonard Kruimer Director 55 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 12,998,787 11,451,447 88.1% 1,147,565 8.8% 88.1%
Shareholders
NameEquities%
Basilea Pharmaceutica AG 1,150,132 8.85%
Black Creek Investment Management, Inc. 583,019 4.49%
Braginsky Family Office AG 393,662 3.03%
The Vanguard Group, Inc. 329,405 2.54%
Norges Bank Investment Management 248,185 1.91%
ACATIS Investment Kapitalverwaltungsgesellschaft mbH 210,047 1.62%
Credit Suisse Asset Management (Schweiz) AG 196,868 1.52%
BlackRock Fund Advisors 167,888 1.29%
Bank J. Safra Sarasin AG (Investment Management) 147,947 1.14%
William Blair Investment Management LLC 134,378 1.03%
Holdings
NameEquities%Valuation
BASILEA PHARMACEUTICA AG (BSLN) 1,150,132 8.85% 52,923,888 USD
Brand Portfolio
In partnership withAllbrands.markets
More brands of Basilea Pharmaceutica AG
Sector Other Biotechnology & Medical Research